IL162141A0 - Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemoterapy - Google Patents
Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemoterapyInfo
- Publication number
- IL162141A0 IL162141A0 IL16214102A IL16214102A IL162141A0 IL 162141 A0 IL162141 A0 IL 162141A0 IL 16214102 A IL16214102 A IL 16214102A IL 16214102 A IL16214102 A IL 16214102A IL 162141 A0 IL162141 A0 IL 162141A0
- Authority
- IL
- Israel
- Prior art keywords
- amino acids
- chemoterapy
- cytotoxic
- formulation
- toxic effects
- Prior art date
Links
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 title abstract 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- 229960002477 riboflavin Drugs 0.000 title abstract 2
- 235000019192 riboflavin Nutrition 0.000 title abstract 2
- 239000002151 riboflavin Substances 0.000 title abstract 2
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 231100000331 toxic Toxicity 0.000 title 1
- 230000002588 toxic effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000002512 chemotherapy Methods 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000969 carrier Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 235000020776 essential amino acid Nutrition 0.000 abstract 1
- 239000003797 essential amino acid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000004143 urea cycle Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/995,010 US20030105104A1 (en) | 2001-11-27 | 2001-11-27 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| PCT/US2002/037354 WO2003045372A1 (en) | 2001-11-27 | 2002-11-21 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL162141A0 true IL162141A0 (en) | 2005-11-20 |
Family
ID=25541300
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16214102A IL162141A0 (en) | 2001-11-27 | 2002-11-21 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemoterapy |
| IL162141A IL162141A (en) | 2001-11-27 | 2004-05-24 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL162141A IL162141A (en) | 2001-11-27 | 2004-05-24 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20030105104A1 (es) |
| EP (1) | EP1450781B1 (es) |
| JP (1) | JP4614660B2 (es) |
| KR (1) | KR100953483B1 (es) |
| CN (1) | CN100358527C (es) |
| AT (1) | ATE330595T1 (es) |
| BR (1) | BR0214430A (es) |
| CA (1) | CA2468133C (es) |
| DE (1) | DE60212693T2 (es) |
| EA (1) | EA009516B1 (es) |
| HU (1) | HU230986B1 (es) |
| IL (2) | IL162141A0 (es) |
| MX (1) | MXPA04004994A (es) |
| NO (1) | NO332858B1 (es) |
| NZ (1) | NZ532833A (es) |
| PL (1) | PL353656A1 (es) |
| RO (1) | RO121173B1 (es) |
| SI (1) | SI21542A (es) |
| UA (1) | UA78977C2 (es) |
| WO (1) | WO2003045372A1 (es) |
| ZA (1) | ZA200404115B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100413866C (zh) * | 2002-08-02 | 2008-08-27 | 中国人民解放军军事医学科学院放射医学研究所 | 核黄素衍生物及其制备方法与应用 |
| US20070248693A1 (en) * | 2003-08-02 | 2007-10-25 | Elizabeth Mazzio | Nutraceutical composition and method of use for treatment / prevention of cancer |
| US20060035981A1 (en) * | 2003-08-02 | 2006-02-16 | Mazzio Elizabeth A | Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment |
| PT2153870E (pt) * | 2004-11-26 | 2014-03-12 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| CN101288013B (zh) * | 2005-09-19 | 2010-12-08 | Cdm光学有限公司 | 基于任务的成像系统 |
| WO2007119378A1 (ja) | 2006-03-15 | 2007-10-25 | Suntory Limited | リボフラビンとセサミン類とを含有する組成物 |
| WO2008050836A1 (fr) * | 2006-10-25 | 2008-05-02 | Ajinomoto Co., Inc. | Agent destiné à l'amélioration des effets secondaires d'un agent chimiothérapeutique |
| JPWO2008105384A1 (ja) * | 2007-02-26 | 2010-06-03 | 協和発酵バイオ株式会社 | シトルリン含有錠剤 |
| EP3342409A1 (en) | 2007-03-15 | 2018-07-04 | Suntory Holdings Limited | Anti-fatigue agent |
| WO2010011927A1 (en) | 2008-07-25 | 2010-01-28 | Noventis, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| JP5882735B2 (ja) | 2008-09-19 | 2016-03-09 | ネステク ソシエテ アノニム | 抗癌治療の間の骨髄麻痺又は好中球減少を阻止又は緩和するための栄養支援 |
| AU2014200578B2 (en) * | 2008-09-19 | 2016-08-11 | Société des Produits Nestlé S.A. | Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |
| EA023051B1 (ru) | 2009-04-03 | 2016-04-29 | Осера Терапьютикс, Инк. | Кристаллические формы фенилацетата l-орнитина и их применение |
| EP2799067B1 (en) | 2009-06-08 | 2019-04-03 | UCL Business PLC | Treatment of brain inflammation using L-Ornithine Phenylacetate |
| US8449512B2 (en) | 2010-04-09 | 2013-05-28 | Davinci Biomedical Research Products Inc. | Stoma stabilitating device and method |
| EP2397458A1 (en) * | 2010-06-21 | 2011-12-21 | Lunamed AG | Organic salts and co-crystals of phenylbutyric acid |
| AU2011280985C1 (en) | 2010-07-22 | 2016-04-21 | Reven Pharmaceuticals, Inc. | Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution |
| EP4406557A2 (en) * | 2010-09-24 | 2024-07-31 | University of Florida Research Foundation, Inc. | Materials and methods for improving gastrointestinal function |
| BR112013008054B1 (pt) | 2010-10-06 | 2019-04-09 | Ocera Therapeutics, Inc. | Composição e processo para produção de sal de acetato de fenil l-ornitina |
| TWI489981B (zh) * | 2010-12-10 | 2015-07-01 | 柏萊迪健康科學有限責任公司 | 使用茉莉酸治療膀胱功能障礙 |
| EP2676664B1 (en) * | 2011-02-17 | 2017-06-21 | EA Pharma Co., Ltd. | Potentiator of antitumor activity of chemotherapeutic agent |
| RU2644635C2 (ru) * | 2011-07-07 | 2018-02-13 | Рисёрч Кансер Инститьют Оф Америка | Системы, способы и составы для лечения рака |
| ES2708756T3 (es) | 2013-03-11 | 2019-04-11 | Univ Florida | Materiales y métodos para mejorar la función pulmonar y para la prevención y/o el tratamiento de complicaciones pulmonares inducidas por radiación |
| BR112016009931B1 (pt) * | 2013-11-08 | 2021-02-02 | Legacy Healthcare Ltd | composição para uso para a inibição da progressão de tumor e redução do tamanho de tumor e para o tratamento de comorbidades do câncer |
| JP6598425B2 (ja) * | 2014-02-27 | 2019-10-30 | 花王株式会社 | 疲労の評価方法 |
| BR112017010761B1 (pt) | 2014-11-24 | 2022-10-18 | Ucl Business Plc | Tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia |
| CA2995823A1 (en) | 2015-08-18 | 2017-02-23 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| CN105495582A (zh) * | 2015-12-11 | 2016-04-20 | 北京康比特体育科技股份有限公司 | 一款抗疲劳、促恢复的保健食品氨基酸组合物 |
| JP7126520B2 (ja) | 2017-05-11 | 2022-08-26 | オセラ セラピューティクス， インコーポレイテッド | Ｌ－オルニチンフェニルアセテートを製造する方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5535049A (en) * | 1978-09-04 | 1980-03-11 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion for cancerous patient |
| JPS58126767A (ja) * | 1982-01-22 | 1983-07-28 | Ajinomoto Co Inc | 肝臓病患者用栄養組成物 |
| ES2033667T3 (es) * | 1985-10-23 | 1993-04-01 | Dr. Kurt Mulli Nachf. Gmbh & Co. Kg | Composicion farmaceutica que contiene fracciones de extractos de timo. |
| US5045468A (en) | 1986-12-12 | 1991-09-03 | Cell Enterprises, Inc. | Protein-free culture medium which promotes hybridoma growth |
| ATE113441T1 (de) * | 1989-10-02 | 1994-11-15 | Sandoz Nutrition Ltd | Proteinhydrolysaten. |
| US5292773A (en) | 1990-02-14 | 1994-03-08 | Hirsch Gerald P | Treating aids and HIV infection with methionine |
| CA2143420C (en) * | 1992-12-23 | 1999-01-19 | Phyllis J. B. Acosta | Medical foods for the nutritional support of infant/toddler metabolic diseases |
| US5571783A (en) * | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| FR2705765B1 (fr) * | 1993-04-29 | 1995-08-18 | Eurofours Sa | Porte de four. |
| US5547927A (en) * | 1993-05-28 | 1996-08-20 | Abbott Laboratories | Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy |
| NZ248605A (en) * | 1993-05-28 | 1994-12-22 | Abbott Lab | Enteral nutritional product comprising protein and fat |
| US5719133A (en) * | 1994-09-21 | 1998-02-17 | Novartis Nutrition Ag | Adolescent dietary composition |
| US5656608B1 (en) | 1995-02-23 | 2000-09-26 | Novartis Nutrition Ltd | Amino acid compositions and methods of treatment using same |
| US5728678A (en) * | 1995-06-06 | 1998-03-17 | Nestec Ltd. | Method and composition for providing nutrition to a renal failure patient |
| US5776913A (en) | 1995-10-10 | 1998-07-07 | Colgate Palmolive Company | Therapeutic diet for metabolic abnormalities found in animals with lymphoma |
| DE69734713T2 (de) * | 1996-05-14 | 2006-07-06 | Burzynski, Stanislaw R., Houston | Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität |
| US5817927A (en) * | 1997-04-11 | 1998-10-06 | Betzdearborn Inc. | Method and apparatus for monitoring water process equipment |
| US5817695A (en) * | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
| DE69910746T2 (de) | 1999-06-26 | 2004-06-17 | B. Braun Melsungen Ag | Wässrige Lösung für parenterale Nahrung |
| GB0009056D0 (en) * | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
| US6377094B1 (en) * | 2002-03-25 | 2002-04-23 | Oak Technology, Inc. | Arbitrary waveform synthesizer using a free-running ring oscillator |
-
2001
- 2001-11-27 US US09/995,010 patent/US20030105104A1/en not_active Abandoned
-
2002
- 2002-04-26 PL PL02353656A patent/PL353656A1/xx not_active Application Discontinuation
- 2002-11-21 SI SI200220037A patent/SI21542A/sl not_active IP Right Cessation
- 2002-11-21 WO PCT/US2002/037354 patent/WO2003045372A1/en active IP Right Grant
- 2002-11-21 HU HU0402240A patent/HU230986B1/hu not_active IP Right Cessation
- 2002-11-21 NZ NZ532833A patent/NZ532833A/en not_active IP Right Cessation
- 2002-11-21 KR KR1020047007754A patent/KR100953483B1/ko active IP Right Grant
- 2002-11-21 DE DE60212693T patent/DE60212693T2/de not_active Expired - Lifetime
- 2002-11-21 MX MXPA04004994A patent/MXPA04004994A/es active IP Right Grant
- 2002-11-21 CA CA2468133A patent/CA2468133C/en not_active Expired - Fee Related
- 2002-11-21 EA EA200400737A patent/EA009516B1/ru not_active IP Right Cessation
- 2002-11-21 JP JP2003546874A patent/JP4614660B2/ja not_active Expired - Fee Related
- 2002-11-21 IL IL16214102A patent/IL162141A0/xx unknown
- 2002-11-21 UA UA20040605059A patent/UA78977C2/uk unknown
- 2002-11-21 EP EP02789801A patent/EP1450781B1/en not_active Expired - Lifetime
- 2002-11-21 CN CNB028236068A patent/CN100358527C/zh not_active Expired - Fee Related
- 2002-11-21 AT AT02789801T patent/ATE330595T1/de not_active IP Right Cessation
- 2002-11-21 BR BR0214430-1A patent/BR0214430A/pt not_active Application Discontinuation
- 2002-11-21 RO ROA200400481A patent/RO121173B1/ro unknown
-
2004
- 2004-05-24 IL IL162141A patent/IL162141A/en not_active IP Right Cessation
- 2004-05-26 ZA ZA2004/04115A patent/ZA200404115B/en unknown
- 2004-06-07 NO NO20042364A patent/NO332858B1/no not_active IP Right Cessation
-
2005
- 2005-04-18 US US11/108,277 patent/US7427619B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL162141A0 (en) | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemoterapy | |
| HK1065483A1 (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
| WO2001027109A3 (de) | Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridin-3-yl)-amin-derivate | |
| TNSN05180A1 (en) | Liquid pharmaceutical formulations of palonosetron | |
| CZ309247B6 (cs) | 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru | |
| GEP20053510B (en) | Substituted Pyrrolopyridinone Derivatives Useful as Phosphodiesterase Inhibitors | |
| BR0305628A (pt) | Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso | |
| WO2005014524A3 (en) | Amino thiol compounds and compositions for use in conjunction with cancer therapy | |
| MXPA03010054A (es) | Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos. | |
| IL150953A0 (en) | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | |
| ATE521624T1 (de) | Peptide und medizinische zusammensetzungen mit denselben | |
| FR12C0064I2 (fr) | Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale | |
| PL1718651T3 (pl) | Pochodne 7H-pirolopirymidyny | |
| MY134690A (en) | Antitumor therapy comprising distamycin derivatives. | |
| MXPA01012936A (es) | Composicion farmaceutica que contiene sibutramina y orlistat. | |
| AU2003218141A8 (en) | Potent, simplified derivatives of immunosuppressive agents | |
| SI1699468T1 (sl) | Farmacevtski sestavek, ki obsega kompleks cink-hialuronan, za zdravljenje multiple skleroze | |
| EP1411956B8 (en) | Use of oversulfated polysaccharides as inhibitors of hiv | |
| MXPA05007253A (es) | Sales novedosas de derivados anticonvulsivantes. | |
| RS20060435A (en) | Compostions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug | |
| WO2004073627A3 (en) | Novel therapeutic method and compositions for topical administration | |
| MX2023013301A (es) | Una pluralidad de particulas tasquinimod y su uso. | |
| ECSP982396A (es) | Composiciones que contienen tetrahidrolipstatina |